share_log

平安好醫生：截至2024年6月30日止六個月期間未經審計中期業績公告

PA GOODDOCTOR: ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FORTHE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 20 16:30

Summary by Moomoo AI

平安健康醫療科技有限公司（「平安好醫生」）公佈截至2024年6月30日止六個月的未經審計中期業績。期內，公司錄得總收入約人民幣2,093.4百萬元，較去年同期下降5.8%。毛利為人民幣673.8百萬元，下降5.8%。期內淨利潤為人民幣60.6百萬元，去年同期為淨虧損人民幣244.9百萬元。公司於2024年6月30日的現金及現金等價物為人民幣3,008.7百萬元。公司表示，戰略業務穩健增長，並通過科技創新推動業務模式和服務流程的優化升級，實現運營效率和服務質量的雙重提升。公司董事會主席李斗先生表示，公司將繼續探索AI能力的提升及其應用場景的開發，賦能醫療服務效率和質量提升，並助力自身及行業內企業數智化轉型升級。
平安健康醫療科技有限公司（「平安好醫生」）公佈截至2024年6月30日止六個月的未經審計中期業績。期內，公司錄得總收入約人民幣2,093.4百萬元，較去年同期下降5.8%。毛利為人民幣673.8百萬元，下降5.8%。期內淨利潤為人民幣60.6百萬元，去年同期為淨虧損人民幣244.9百萬元。公司於2024年6月30日的現金及現金等價物為人民幣3,008.7百萬元。公司表示，戰略業務穩健增長，並通過科技創新推動業務模式和服務流程的優化升級，實現運營效率和服務質量的雙重提升。公司董事會主席李斗先生表示，公司將繼續探索AI能力的提升及其應用場景的開發，賦能醫療服務效率和質量提升，並助力自身及行業內企業數智化轉型升級。
Ping An Health Medical Technology Co., Ltd. ("Ping An Good Doctor") announced the unaudited interim performance for the six months ended June 30, 2024. During the period, the company recorded total revenue of approximately RMB 2,093.4 million, a decrease of 5.8% compared to the same period last year. Gross profit was RMB 673.8 million, a decrease of 5.8%. Net profit for the period was RMB 60.6 million, compared to a net loss of RMB 244.9 million in the same period last year. As of June 30, 2024, the company's cash and cash equivalents were RMB 3,008.7 million. The company stated that its strategic business has shown steady growth, and through technological innovation, it has optimized and upgraded its business model and service processes, achieving dual improvements in operational efficiency and...Show More
Ping An Health Medical Technology Co., Ltd. ("Ping An Good Doctor") announced the unaudited interim performance for the six months ended June 30, 2024. During the period, the company recorded total revenue of approximately RMB 2,093.4 million, a decrease of 5.8% compared to the same period last year. Gross profit was RMB 673.8 million, a decrease of 5.8%. Net profit for the period was RMB 60.6 million, compared to a net loss of RMB 244.9 million in the same period last year. As of June 30, 2024, the company's cash and cash equivalents were RMB 3,008.7 million. The company stated that its strategic business has shown steady growth, and through technological innovation, it has optimized and upgraded its business model and service processes, achieving dual improvements in operational efficiency and service quality. Mr. Li Dou, Chairman of the Board of Directors, said that the company will continue to explore the enhancement of AI capabilities and the development of application scenarios, empowering the improvement of medical service efficiency and quality, and promoting the digital transformation and upgrading of itself and enterprises in the industry.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated